within Pharmacolibrary.Drugs.D_Dermatologicals.D05A_AntipsoriaticsForTopicalUse.D05AX55_TazaroteneAndUlobetasol;

model TazaroteneAndUlobetasol
  extends Pharmacolibrary.Drugs.ATC.D.D05AX55;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>D05AX55</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tazarotene and ulobetasol is a fixed-combination topical medication approved for the treatment of plaque psoriasis in adults. Tazarotene is a third-generation retinoid that modulates keratinocyte differentiation and proliferation, while ulobetasol is a potent topical corticosteroid with anti-inflammatory properties. The combination is used for short-term topical management of psoriasis and is currently an approved treatment in several countries.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed publications currently report full pharmacokinetic models or parameters for the fixed-combination tazarotene and ulobetasol product in humans. Limited data on systemic absorption of the individual components after topical administration suggest low bioavailability, but key PK parameters are not available.</p><h4>References</h4><ol><li><p>Reddy, V, et al., &amp; Bhutani, T (2020). Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults. <i>Clinical, cosmetic and investigational dermatology</i> 13 391–398. DOI:<a href=\"https://doi.org/10.2147/CCID.S252426\">10.2147/CCID.S252426</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32606876/\">https://pubmed.ncbi.nlm.nih.gov/32606876</a></p></li><li><p>Hecker, D, et al., &amp; Lebwohl, M (2000). In vitro compatibility of tazarotene with other topical treatments of psoriasis. <i>Journal of the American Academy of Dermatology</i> 42(6) 1008–1011. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10827404/\">https://pubmed.ncbi.nlm.nih.gov/10827404</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end TazaroteneAndUlobetasol;
